We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MTD Second Quarter Earnings Beat Estimates on China-Led Sales Growth
Read MoreHide Full Article
Key Takeaways
MTD beat Q2 earnings estimates as China and emerging markets drove organic sales growth.
Mettler-Toledo expanded margins through pricing, productivity and lower tariffs despite higher costs.
MTD raised 2026 sales growth and adjusted earnings guidance after the stronger second quarter.
Mettler-Toledo International (MTD - Free Report) reported second-quarter 2026 adjusted earnings of $11.46 per share, which beat the Zacks Consensus Estimate of $10.78 by 6.31%. Adjusted earnings increased 14% year over year.
Net sales of $1.03 billion increased 4% year over year but missed the Zacks Consensus Estimate of $1.03 billion by 0.46%. Better-than-expected organic sales growth, including strong demand in China and emerging markets, supported the quarter.
MTD Navigates a More Favorable Regional Backdrop
On a local-currency basis, MTD's sales increased 3% in the Americas, 4% in Europe and 10% in Asia/Rest of World in the quarter. Excluding acquisitions and one-time tariff refunds to customers, organic local-currency sales increased 4%, including 1% growth in the Americas and 9% growth in Asia/Rest of World.
By geography, Americas sales declined to $402 million from $414 million, accounting for 39% of total revenues. Europe sales increased to $294 million from $274 million and represented 29% of revenues, while Asia/Rest of World sales rose to $331 million from $295 million, contributing 32% of total revenues.
Mettler-Toledo International, Inc. Price, Consensus and EPS Surprise
Laboratory sales increased to $553 million from $538 million in the prior-year quarter. Industrial sales improved to $418 million from $395 million, while Food Retail revenues increased to $57 million from $51 million.
On an organic local-currency basis, Laboratory sales increased 4%, Industrial sales rose 3%, including 4% growth in Core Industrial and 1% growth in Product Inspection, while Food Retail sales climbed 11%. Service revenues increased 9%, or 7% organically.
Management noted that China delivered 9% growth, supported by Industrial demand, while emerging markets outside China also posted high-single-digit growth. Improved conditions in biopharma, automation, semiconductor, batteries and food manufacturing markets also aided performance.
MTD Expands Margins Despite Higher Expenses
Adjusted gross profit increased to $625.7 million from $579.9 million. Adjusted gross margin expanded 30 basis points year over year to 59.3%, benefiting from pricing, lower tariff rates, productivity initiatives and volume growth, partly offset by higher transportation costs.
Research and development expenses increased to $53 million from $49.3 million. Selling, general and administrative expenses rose to $263.3 million from $247.3 million.
Adjusted operating profit increased 9% year over year to $309.3 million. Adjusted operating margin expanded 50 basis points to 29.3%. Reported diluted earnings per share were $11.55 compared with $9.76 in the prior-year quarter.
Mettler-Toledo Balance Sheet Remains Solid
As of June 30, 2026, cash and cash equivalents were $51.4 million compared with $60.5 million as of March 31, 2026. Long-term debt declined sequentially to $2.04 billion from $2.16 billion.
Year-to-date adjusted free cash flow totaled $367 million. Management noted that free cash flow was affected by the timing of tax payments, which were $55 million higher than the prior year.
The company also increased its planned share repurchases for 2026 to $875 million from the annualized first-half pace of $825 million.
MTD's Q3 & FY26 Guidance
Management cautioned that market conditions remain uncertain and could change quickly, but guided for third-quarter 2026 local-currency sales growth of approximately 4%. Adjusted earnings for the third quarter are forecast to be in the range of $12-$12.15 per share, implying 8-9% growth year over year.
For 2026, MTD raised its local-currency sales growth outlook to approximately 4-5% from the prior view of approximately 4%, and raised adjusted earnings guidance to $47.15-$47.50 per share, representing growth of 10-11%, from the prior outlook of $46.30-$46.95.
Shares of Progyny have surged 21.2% year to date. The Zacks Consensus Estimate for Progyny’s 2026 earnings is pegged at $2.04 per share, up by 3.55% over the past 30 days, indicating an increase of 7.94% year over year.
Shares of Centene have jumped 51.2% year to date. The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $4.71 per share, up 36.13% over the past 30 days, indicating a rise of 126.44% year over year.
GETINGE shares have appreciated 5.2% year to date. The Zacks Consensus Estimate for GETINGE’s 2026 earnings is pegged at $1.38 per share, up by 9.52% over the past 30 days, indicating an increase of 20% year over year.
View the Zacks #1 Rank List
Image: Bigstock
MTD Second Quarter Earnings Beat Estimates on China-Led Sales Growth
Key Takeaways
Mettler-Toledo International (MTD - Free Report) reported second-quarter 2026 adjusted earnings of $11.46 per share, which beat the Zacks Consensus Estimate of $10.78 by 6.31%. Adjusted earnings increased 14% year over year.
Net sales of $1.03 billion increased 4% year over year but missed the Zacks Consensus Estimate of $1.03 billion by 0.46%. Better-than-expected organic sales growth, including strong demand in China and emerging markets, supported the quarter.
MTD Navigates a More Favorable Regional Backdrop
On a local-currency basis, MTD's sales increased 3% in the Americas, 4% in Europe and 10% in Asia/Rest of World in the quarter. Excluding acquisitions and one-time tariff refunds to customers, organic local-currency sales increased 4%, including 1% growth in the Americas and 9% growth in Asia/Rest of World.
By geography, Americas sales declined to $402 million from $414 million, accounting for 39% of total revenues. Europe sales increased to $294 million from $274 million and represented 29% of revenues, while Asia/Rest of World sales rose to $331 million from $295 million, contributing 32% of total revenues.
Mettler-Toledo International, Inc. Price, Consensus and EPS Surprise
Mettler-Toledo International, Inc. price-consensus-eps-surprise-chart | Mettler-Toledo International, Inc. Quote
Mettler-Toledo Sees Strength Across Businesses
Laboratory sales increased to $553 million from $538 million in the prior-year quarter. Industrial sales improved to $418 million from $395 million, while Food Retail revenues increased to $57 million from $51 million.
On an organic local-currency basis, Laboratory sales increased 4%, Industrial sales rose 3%, including 4% growth in Core Industrial and 1% growth in Product Inspection, while Food Retail sales climbed 11%. Service revenues increased 9%, or 7% organically.
Management noted that China delivered 9% growth, supported by Industrial demand, while emerging markets outside China also posted high-single-digit growth. Improved conditions in biopharma, automation, semiconductor, batteries and food manufacturing markets also aided performance.
MTD Expands Margins Despite Higher Expenses
Adjusted gross profit increased to $625.7 million from $579.9 million. Adjusted gross margin expanded 30 basis points year over year to 59.3%, benefiting from pricing, lower tariff rates, productivity initiatives and volume growth, partly offset by higher transportation costs.
Research and development expenses increased to $53 million from $49.3 million. Selling, general and administrative expenses rose to $263.3 million from $247.3 million.
Adjusted operating profit increased 9% year over year to $309.3 million. Adjusted operating margin expanded 50 basis points to 29.3%. Reported diluted earnings per share were $11.55 compared with $9.76 in the prior-year quarter.
Mettler-Toledo Balance Sheet Remains Solid
As of June 30, 2026, cash and cash equivalents were $51.4 million compared with $60.5 million as of March 31, 2026. Long-term debt declined sequentially to $2.04 billion from $2.16 billion.
Year-to-date adjusted free cash flow totaled $367 million. Management noted that free cash flow was affected by the timing of tax payments, which were $55 million higher than the prior year.
The company also increased its planned share repurchases for 2026 to $875 million from the annualized first-half pace of $825 million.
MTD's Q3 & FY26 Guidance
Management cautioned that market conditions remain uncertain and could change quickly, but guided for third-quarter 2026 local-currency sales growth of approximately 4%. Adjusted earnings for the third quarter are forecast to be in the range of $12-$12.15 per share, implying 8-9% growth year over year.
For 2026, MTD raised its local-currency sales growth outlook to approximately 4-5% from the prior view of approximately 4%, and raised adjusted earnings guidance to $47.15-$47.50 per share, representing growth of 10-11%, from the prior outlook of $46.30-$46.95.
Zacks Rank & Other Stocks to Consider
MTD currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader Zacks Medical sector are Progyny (PGNY - Free Report) , Centene (CNC - Free Report) and GETINGE (GNGBY - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Progyny have surged 21.2% year to date. The Zacks Consensus Estimate for Progyny’s 2026 earnings is pegged at $2.04 per share, up by 3.55% over the past 30 days, indicating an increase of 7.94% year over year.
Shares of Centene have jumped 51.2% year to date. The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $4.71 per share, up 36.13% over the past 30 days, indicating a rise of 126.44% year over year.
GETINGE shares have appreciated 5.2% year to date. The Zacks Consensus Estimate for GETINGE’s 2026 earnings is pegged at $1.38 per share, up by 9.52% over the past 30 days, indicating an increase of 20% year over year.